- Slight decrease in the global percentage of female employees in senior management roles from 34% in 2022 to 32% in 2023 due to the acquisition of Idorsia Pharmaceutical’s Japan, Korea and APAC businesses.
- Potential for increased regulatory frameworks on energy use and increased expected energy costs due to carbon taxes and CO2 emission regulations.
Nxera Pharma
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Nxera Pharma disclosed greenhouse gas emissions of 800.66 t-CO2e in FY2023. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
800.66 t-CO2e in FY2023
2023
Water Usage
1.8K m3 at UK R&D facility in 2023
2023
Energy Use
1.7M kWh (Electricity) and 1369047 kWh (Gas) at UK R&D facility in 2023
2023
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 800.66 t-CO2e in FY2023 |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Obtained My Green Lab Certification at Green standard for both chemistry and biology laboratories in the UK R&D facility.
- Reduced CO2 emissions from R&D facility per person from 3.54 tons in 2022 to 3.26 tons in 2023.
🎯 Climate & Sustainability Targets
📅 Medium-term
- Maintain Female Senior Management Roles (Global) at >30%
🌱 ESG Focus Areas
Environmental ManagementDiversity, Equity and Inclusion (DEI)Creating innovative pharmaceuticals for patientsEquity and transparency to all stakeholders